Read more
Informationen zum Autor Dr Sotiris Missailidis. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK. Klappentext Krebs steht bei den Todesursachen weltweit an zweiter Stelle. Die Forschung konzentriert sich zunehmend darauf, die Entstehung von Krebs ganzheitlich zu betrachten, bekannte Krebsmedikamente auf den Prüfstand zu stellen und Medikamente und kombinierte Therapieansätze zu entwickeln. Zusammenfassung Written by the winner of the 2008 Mike Price Fellowship The need to re-address known anti-cancer agents and discover new ones are of paramount importance. Anticancer Therapeutics provides a comprehensive overview of the wealth of information currently available on this important and fast-moving subject. Inhaltsverzeichnis Forward xiii Acknowledgements xv List of contributors xvii Section I: Development of Anticancer Therapeutics 1 1 Exploring the Potential of Natural Products in Cancer Treatment 3 Fotini N. Lamari and Paul Cordopatis 1.1 Introduction 3 1.2 Sources 4 1.3 Different Approaches to the Search for Bioactive Natural Products 6 1.4 Methodologies of Lead Compound or New Drug Identification 10 1.5 Chemoprevention - A New Area for Natural Product Research 13 1.6 Concluding Remarks 13 2 Combinatorial Approaches to Anticancer Drug Design 17 Sotiris Missailidis 2.1 Introduction 17 2.2 Combinatorial Approaches for Small Molecule Drug Design 17 2.3 Display Technologies 21 2.4 Aptamer Selection 23 2.5 Conclusions 27 3 Rational Approaches to Anticancer Drug Design/in silico Drug Development 29 Stefano Alcaro, Anna Artese and Francesco Ortuso 3.1 Introduction 29 3.2 Approaches to the Drug Discovery Process in Anticancer Research 31 3.3 Ligand-based Examples 32 3.4 Structure-based Examples 36 3.5 Conclusions 44 Section II: Anticancer Therapeutics 47 4 Introduction to Anticancer Therapeutics 49 Teni Boulikas 4.1 Problems in cancer 49 4.2 Cancer treatments 51 4.3 Classification of chemotherapy drugs 53 5 Platinum Drugs 55 Teni Boulikas, Alexandros Pantos, Evagelos Bellis and Petros Christofis 5.1 Cisplatin 55 5.2 Lipoplatin 57 5.3 Carboplatin 61 5.4 Oxaliplatin 62 5.5 Lipoxal 62 5.6 New Platinum Compounds 64 5.7 Cisplatin Resistance and Chemotherapy 70 6 Antimicrotubule Agents 79 Iain Brown, Jay N Sangrithi-Wallace and Andrew C Schofield 6.1 Taxanes 79 6.2 Vinca Alkaloids 82 6.3 Mechanisms of Resistance to Antimicrotubule Agents 86 7 Antimetabolites in Cancer Therapy 91 Jessica Scaife and David Kerr 7.1 Introduction 91 7.2 Folate Antagonists 92 7.3 Pyrimidine Antagonists 96 7.4 Purine Antagonists 104 7.5 Summary 109 8 Antitumour Antibiotics 111 Manuel M. Paz 8.1 Introduction 111 8.2 Actinomycin 111 8.3 Mitomycin c 112 8.4 Bleomycin 115 8.5 Anthracyclines 118 8.6 Trabectedin (Ecteinascidin, ET-743) 121 8.7 Camptothecins 123 8.8 Podophyllotoxins 124 9 Alkylating Agents 133 Ana Paula Francisco, Maria de Jesus Perry, Rui Moreira and Eduarda Mendes 9.1 Introduction 133 9.2 Nitrogen Mustards 133 9.3 Methylmelamines and Ethylenimines 140 9.4 Methylhydrazine Derivatives 141 9.5 Alkylsulfonates 143 9.6 Nitrosoureas 144 9.7 Triazenes 149 10 Hormone Therapies 159 George C. Zografos, Nikolaos V. Michalopoulos and Flora Zagouri 10.1 Introduction 159 10.2 Oestrogen Receptor Targeted Therapeutics 160 10...
